Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial).
Okuma HS, Watanabe K, Tsuchihashi K, Machida R, Sadachi R, Hirakawa A, Ariyama H, Kanai M, Kamikura M, Anjo K, Hiramitsu A, Sekine S, Okita N, Mano H, Nishikawa H, Nakamura K, Yonemori K.
Okuma HS, et al. Among authors: yonemori k.
Clin Cancer Res. 2023 Dec 15;29(24):5079-5086. doi: 10.1158/1078-0432.CCR-23-1807.
Clin Cancer Res. 2023.
PMID: 37819940
Free PMC article.
Clinical Trial.